| Ytd | 14.37% | |
| 1y | 12.20% |
| Open | 348.25 | Prev Close | 356.01 | Low | 343.98 | High | 349.27 | Mkt Cap | 37.13B |
| Vol | 298.05K | Avg Vol | 341.35K | EPS | 5.68 | P/E | 61.18 | Forward P/E | 33.79 |
| Beta | 0.50 | Short Ratio | 2.39 | Inst. Own | 32.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 302.74 | 200-d Avg | 315.19 | 1yr Est | 433.02 |
ONC News
Companies also enter a separate regional rights agreement granting BeOne exclusive development and c
SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Na
Dimensional Fund Advisors LP increased its stake in BeOne Medicines Ltd. - Sponsored ADR (NASDAQ: ON
TD Cowen analyst Yaron Werber maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the pr
RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and
Truist Securities analyst Gregory Renza maintains BeOne Medicines (NASDAQ:ONC) with a Buy and rai
Guggenheim analyst Michael Schmitz maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises t
Citizens analyst Reni J. Benjamin maintains BeOne Medicines (NASDAQ:ONC) with a Market Outperform
BeOne Medicines NASDAQ: ONC reported second-quarter revenue of $1.7 billion, up 30% from a year earl
BeOne Medicines AG (ONC) Q2 2026 Earnings Call Transcript
While the top- and bottom-line numbers for BeOne Medicines Ltd. - Sponsored ADR (ONC) give a sense o
BeOne Medicines (NASDAQ:ONC) raises FY2026 sales outlook from $6.300 billion-$6.500 billion to $6.60
BeiGene (NASDAQ:ONC) reported quarterly earnings of $3.84 per share which beat the analyst consensus
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. announced financial result
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for BeOne Medicines Ltd. - Spons
Arrowstreet Capital Limited Partnership grew its stake in BeOne Medicines Ltd. - Sponsored ADR (NASD
JP Morgan analyst Jessica Fye maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises
FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification a
The expansion will increase BeOne's production capacity to manufacture its medicines and is expe
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines, Ltd. announced a $300 million
Executed under pre-established trading plan, this sale reduces the chief executive's direct holdings
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160;
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160;
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160;
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160;
BeOne Medicines AG (ONC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Tra
BeOne Medicines Ltd. - Sponsored ADR (ONC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflec
BeOne Medicines AG (ONC) Discusses Solid Tumor Portfolio Progress and R&D Pipeline Strategy at ASCO
BeOne Medicines NASDAQ: ONC used an investor event at ASCO to outline what executives described as a
Summit Therapeutics' shares rose as much as 7% before the bell after its ivonescimab therapy with Ch
